Volume 16, Number 9—September 2010
Dispatch
Increasing Incidence of Mucormycosis in University Hospital, Belgium
Veroniek Saegeman, Johan Maertens, Wouter Meersseman, Isabel Spriet, Eric Verbeken, and Katrien Lagrou
Table
Specific annual incidence rate of mucormycosis cases per risk group in a hospital in Belgium, 2000–2008*
| Year | Diabetes mellitus | Solid organ transplantation | Hematologic disorder/ malignancy | HSCT |
|---|---|---|---|---|
| 2000 | 0/3,087 | 0/235 | 1/684 | 0/96 |
| 2001 | 0/3,328 | 0/217 | 2/557 | 1/86 |
| 2002 | 0/3,319 | 0/207 | 0/650 | 0/87 |
| 2003 | 0/3,662 | 0/245 | 0/775 | 0/118 |
| 2004 | 1/3,845 | 0/217 | 0/787 | 0/126 |
| 2005 | 1/4,121 | 1/191 | 1/853 | 0/103 |
| 2006 | 0/4,235 | 2/251 | 5/1,061 | 3/91 |
| 2007 | 0/4,328 | 0/279 | 0/942 | 0/121 |
| 2008 |
0/4,477 |
1/267 |
3/859 |
1/116 |
| p value for the increase in | ||||
| No. patients per risk group | <0.01 | 0.12 | <0.01 | 0.19 |
| Specific annual incidence rate | 0.81 | 0.11 | 0.91 | 0.55 |
*Values are no. cases per risk group/no. patients admitted per year with that risk factor, unless otherwise indicated. Data for risk group patients based on codes from the International Classification of Diseases, 9th Revision, Clinical Modification, available 2000–2008. HSCT, hematopoietic stem cell transplantation.
Page created: August 28, 2011
Page updated: August 28, 2011
Page reviewed: August 28, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.